Skip to content
10-K

Annual Report

Faeth Therapeutics, Inc. FTH SNSE

0001193125-26-132014

← back to feed
Filed
Mar 30, 2026 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Diluted FY 2025 · Dec 31, 2025 1.26M sh
Shares Diluted restated FY 2025 · Dec 31, 2024 1.26M sh
Capex FY 2025 · Dec 31, 2025 $16K
Capex FY 2025 · Dec 31, 2024 $146K
Operating Cash Flow FY 2025 · Dec 31, 2025 −$20.45M
Operating Cash Flow FY 2025 · Dec 31, 2024 −$24.67M
Cash And Equivalents FY 2025 · Dec 31, 2025 $8.67M
Cash And Equivalents FY 2025 · Dec 31, 2024 $9.99M
Stockholders Equity FY 2025 · Dec 31, 2025 $18.59M
Stockholders Equity FY 2025 · Dec 31, 2024 $38.39M
Stockholders Equity FY 2025 · Dec 31, 2023 $64.9M
Current Liabilities FY 2025 · Dec 31, 2025 $4.25M
Current Liabilities FY 2025 · Dec 31, 2024 $5.45M
Total Liabilities FY 2025 · Dec 31, 2025 $4.31M
Total Liabilities FY 2025 · Dec 31, 2024 $6.98M
Current Assets FY 2025 · Dec 31, 2025 $21.51M
Current Assets FY 2025 · Dec 31, 2024 $41.93M
Total Assets FY 2025 · Dec 31, 2025 $22.9M
Total Assets FY 2025 · Dec 31, 2024 $45.36M
Eps Diluted FY 2025 · Dec 31, 2025 −$16.72
Eps Diluted restated FY 2025 · Dec 31, 2024 −$24.01
Eps Basic FY 2025 · Dec 31, 2025 −$16.72
Eps Basic restated FY 2025 · Dec 31, 2024 −$24.01
Sga Expense FY 2025 · Dec 31, 2025 $11.33M
Sga Expense FY 2025 · Dec 31, 2024 $13.04M
Net Income FY 2025 · Dec 31, 2025 −$21.09M
Net Income FY 2025 · Dec 31, 2024 −$30.16M
Operating Income FY 2025 · Dec 31, 2025 −$22.29M
Operating Income FY 2025 · Dec 31, 2024 −$32.61M